CNICF yields 1.07% · JNJ yields 2.13%● Live data
📍 CNICF pulled ahead of the other in Year 1
Combined, CNICF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CNICF + JNJ for your $10,000?
China International Capital Corporation Limited provides financial services in Mainland China and internationally. The company operates through six segments: Investment Banking; Equities; Fixed Income, Commodities, and Currencies (FICC); Asset Management; Private Equity; and Wealth Management. The Investment Banking segment provides investment banking services, including equity financing, debt, and structured financing and financial advisory services. The Equity segment offers investment research, sales, trading, and products and cross-border services, including institutional trading and capital services, such as primary brokerage, over-the-counter derivatives, capital introduction, and market-making transactions. The FICC segment provides fixed-income products, such as interest rate, credit, and structured products, as well as on overseas exchange and commodities. The Asset Management segment engages in the social security and annuity investment management, institutional entrusted investment management, overseas asset management, retail and mutual fund businesses, etc. The Private Equity segment provides corporate equity funds, fund of funds, dollar funds, real estate funds, infrastructure funds, etc. The Wealth Management segment offers wealth transactional, capital, and product configuration services. The company serves domestic and overseas investors, and corporations and institutional clients, as well as retail clients, families, and corporate clients. China International Capital Corporation Limited was incorporated in 1995 and is headquartered in Beijing, the People's Republic of China.
Full CNICF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.